Dr. Schneiderman on Cancer Drugs and Futility Policies

Video

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

Schneiderman says that physicians can affect sick patients in many ways, but if the patient is too sick to benefit from a treatment, then that treatment should be declared futile.

At UCSD, there is a futility policy in place that states any treatment that does not have a reasonable chance of benefitting a patient should be considered futile and not obligatory. The American Medical Association’s Code of Medical Ethics says all hospitals should have a futility policy, Schneiderman says.

Physicians are sometimes concerned that a patient, or, more likely, a family will demand a treatment. The fact remains, Schneiderman says, that a patient or family can refuse a treatment but cannot demand a treatment.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD